
|Videos|April 4, 2019
Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma
Author(s)Mark H. O'Hara, MD
Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
Advertisement
Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Anbenitamab Injection Combo Meets pCR End Point in HER2+ Breast Cancer
2
EMERALD-3 Durvalumab Combo Improves PFS in Embolization-Eligible HCC
3
ELCC 2026: Key Updates Across Non–Small Cell Lung Cancer Populations
4
Relacorilant/Nab-Paclitaxel Offers New Option in Platinum-Resistant Ovarian Cancer
5






















































